Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Summary

This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2018-04-25

Primary completion

2027-06-30

Completion

2027-06-30

Drugs

Indications